Core Viewpoint - Citius Pharmaceuticals, Inc. has reported its first revenue of $3.9 million following the launch of LYMPHIR, marking a significant milestone in its transition to a revenue-generating company [1]. Business Highlights - The company successfully launched LYMPHIR in December 2025, generating initial sales through a nationwide network of distributors [1]. - Citius Pharma anticipates growth opportunities through early signals from investigator-initiated studies and potential international market expansion [1]. - The company is focused on advancing its late-stage pipeline, which includes Mino-Lok and Halo-Lido, while maintaining financial stewardship [1]. Financial Highlights - For the fiscal first quarter ended December 31, 2025, Citius reported a net loss of $8.2 million, or $(0.41) per share, an improvement from a net loss of $9.8 million, or $(1.30) per share, in the prior-year period [1]. - Stock-based compensation expenses increased to $4.3 million from $2.5 million year-over-year, while general and administrative expenses rose slightly to $5.7 million [1]. - Research and development expenses decreased to $1.6 million from $2.1 million, reflecting reduced clinical development activity [1]. Cash Flow and Financing - The company generated net proceeds of approximately $20.9 million from equity financings during the quarter [1]. - Cash and cash equivalents totaled $7.7 million as of December 31, 2025, compared to $4.3 million at the end of the previous quarter [1]. Market Potential - The initial market for LYMPHIR is estimated to exceed $400 million and is considered underserved by existing therapies [1]. - Citius Oncology's robust intellectual property protections, including orphan drug designation and pending patents, support its competitive positioning in the oncology market [1].